Health
globalreutersSeptember 13, 20241 Mins read
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders
globalreutersSeptember 13, 20241 Mins read 
Bicara Therapeutics’ IPO raised $315 million raised for Phase 3 testing of a bifunctional antibody drug with potential to become a first-line treatment for head and neck cancers. Zenas BioPharma and MBX Biosciences also went public; all three companies upsized their IPOs.
The post 3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders appeared first on MedCity News.
Related Articles
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
Kura Oncology already had a broad development plan for ziftomenib in leukemias,...
How Much More Would People Pay in Premiums if the ACA’s Enhanced Subsidies Expired?
Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace...
Everything You Need to Know About Hip Replacement Surgery in India
Hip replacement surgery is one of the most common and successful medical...
Speculation on RFK Jr. as HHS Secretary
From Tyler Cowen at Marginal Revolution: One of the problems with an...
Leave a comment